Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Gilead Sciences (NQ:GILD)

133.06 +2.54 (+1.95%)
Streaming Delayed Price Updated: 9:32 AM EDT, Jul 28, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Gilead Sciences

< Previous 1 2 3 4 5 6 7 8 9
...
55 56 Next >
News headline image
Vanguard Health Care ETF Outperforms VanEck Biotech on Returns, Yield, and Fees ↗
VHT's diversified portfolio of 411 holdings delivered $1,278 from a $1,000 investment over five years, while its lower expense ratio and higher dividend yield appeal to income investors. 
Via The Motley Fool
Topics ETFs
News headline image
Global Prophylactic HIV Drug Market Growing at 7.8% CAGR Through 2034 ↗
According to a new report from Intel Market Research, the global Prophylactic HIV Drug Market was valued at USD 3.45 billion in 2025 and is projected to re 
Via Talk Markets
Gilead Sciences Inc (NASDAQ:GILD): A Quality Dividend Stock for Income Investors ↗
Via Chartmill
News headline image
iShares Global Healthcare ETF vs VanEck Biotech ETF: Which ETF Is Better for Profiting With Healthcare in 2026? ↗
VanEck's concentrated biotech portfolio surged 30.8% in one year but endured a 39.9% drawdown. iShares offers steadier global healthcare exposure with a 1.5% dividend yield. 
Via The Motley Fool
Topics ETFs
Gilead Sciences Inc (NASDAQ:GILD): A Sustainable Dividend Leader in the Biotechnology Sector ↗
Via Chartmill
News headline image
Is the iShares Healthcare ETF or the Invesco Nasdaq Biotech ETF the Better Bet for Investors in 2026? ↗
One offers global diversification and higher income; the other delivers focused biotech exposure with lower costs and stronger recent gains. 
Via The Motley Fool
Topics ETFs
News headline image
Gilead, Merck Advance Potential Blockbuster Weekly HIV Pill ↗
Gilead & Merck Phase 3 data shows once-weekly ISL/LEN matches daily HIV meds in viral suppression through 48 weeks. 
Via Benzinga
News headline image
3 Market-Beating Stocks with Solid Fundamentals
The best-performing stocks typically have robust sales growth, increasing margins, and rising returns on capital, and those that can maintain this trifecta y... 
Via StockStory
Topics Energy
News headline image
Here's How Much $100 Invested In Gilead Sciences 20 Years Ago Would Be Worth Today ↗
Gilead Sciences (NASDAQ:GILD) has outperformed the market over the past 20 years by 2.19% on an annualized basis producing an average annual return of 11.43%. Currently, Gilead Sciences has a market... 
Via Benzinga
News headline image
IHE vs. BBH: Which Healthcare ETF Is the Better Buy Right Now? ↗
BBH offers concentrated exposure to biotech, while IHE provides higher income with lower volatility by focusing on established drugmakers. 
Via The Motley Fool
Topics ETFs
News headline image
IXJ vs. IBBQ: Global Healthcare vs. Biotech -- Which ETF Is the Better Buy? ↗
IBBQ's concentrated biotech play has delivered a higher one-year return, while IXJ'S diversified global healthcare fund has been much less volatile. 
Via The Motley Fool
Topics ETFs
News headline image
Gilead Leads The Battle Vs. HIV. But Rivals Are On The Move. ↗
Gilead stock is closely tied to its HIV treatments. But with Biktarvy's patent expirations looming, can the giant survive? 
Via Investor's Business Daily
Topics Intellectual Property
News headline image
Kalshi Will Let Traders Bet on FDA Drug Approvals Despite Critics' Insider Trading Warnings ↗
Kalshi is expanding into biotech with contracts on FDA drug approvals from Sanofi and Gilead, as critics warn the wagers invite insider trading. 
Via Benzinga
News headline image
Invesco Healthcare ETF vs VanEck Biotech: Which ETF Will Deliver the Healthiest Returns for 2026? ↗
RSPH offers 60 diversified holdings with lower volatility, while BBH concentrates on 25 biotech leaders with stronger recent returns. 
Via The Motley Fool
Topics ETFs
News headline image
Spotting Winners: Gilead Sciences (NASDAQ:GILD) And Therapeutics Stocks In Q1
Quarterly earnings results are a good time to check in on a company’s progress, especially compared to its peers in the same sector. Today we are looking at ... 
Via StockStory
Topics Artificial Intelligence
News headline image
Many Investors Are Still Treating Gilead Sciences Like a Has-Been HIV Stock. 4 Drug Launches This Year Could Prove Them Wrong. ↗
Gilead's expansion beyond HIV therapies will surprise many investors. 
Via The Motley Fool
Topics Intellectual Property
News headline image
Which is Best for Investors: Healthcare Stability (XLV) or Biotech Growth (IBBQ)? ↗
IBBQ surged 54.5% in one year but carries deeper drawdowns. XLV offers broader diversification, lower costs, and double dividend yield for steadier returns. 
Via The Motley Fool
Topics ETFs
News headline image
Which is the Better Choice for Healthcare Investors? IYH or BBH? ↗
BBH delivered 33.6% returns but swung 39.9% lower; IYH's 100 holdings offer steadier performance with 1.2% dividend yield. 
Via The Motley Fool
Topics ETFs
What's going on in today's session: S&P500 movers ↗
Via Chartmill
News headline image
2 Recession-Resistant Dividend Stocks to Buy and Hold ↗
You don't need to predict a recession to prepare your portfolio. These two stocks can help. 
Via The Motley Fool
Topics Economy
News headline image
IHE vs. IBB: Which iShares Healthcare ETF Is the Better Buy? ↗
Established pharmaceutical giants have delivered lower volatility and higher income than clinical-stage biotech exposure over the past five years. 
Via The Motley Fool
Topics ETFs
News headline image
Which Healthcare ETF Is the Better Buy: Invesco's IBBQ or State Street's XPH? ↗
IBBQ offers lower costs and broader diversification, while XPH delivered stronger 1-year returns with less volatility. 
Via The Motley Fool
Topics ETFs
News headline image
BBH vs. XPH: Which Healthcare ETF Is Better for Beginners? ↗
Broader diversification and lower volatility set these healthcare ETFs apart, with each fund targeting a distinct segment of the industry. 
Via The Motley Fool
Topics ETFs
Stay informed with the top movers within the S&P500 index on Tuesday. ↗
Via Chartmill
News headline image
Generic Fears Overdone? Gilead Stock Has More Room to Run, Analyst Says ↗
HSBC upgrades Gilead Sciences (GILD) to Buy, raising its price target to $155 on strong long-acting HIV & oncology potential. 
Via Benzinga
News headline image
FHLC vs. BBH: Which Healthcare ETF Is the Better Buy? ↗
Compare fees, diversification, and risk between these two leading healthcare ETFs. 
Via The Motley Fool
Topics ETFs
News headline image
If You Invested $1000 In Gilead Sciences Stock 20 Years Ago, You Would Have This Much Today ↗
Gilead Sciences (NASDAQ:GILD) has outperformed the market over the past 20 years by 2.07% on an annualized basis producing an average annual return of 11.3%. Currently, Gilead Sciences has a market... 
Via Benzinga
News headline image
SPDR Health Care ETF Tops iShares Biotech in Long-Term Returns ↗
Compare portfolio diversity, risk profiles, and income potential as you weigh these two leading healthcare ETFs. 
Via The Motley Fool
Topics ETFs
News headline image
Gilead's Trodelvy Expands Reach With New FDA Approval In Breast Cancer ↗
FDA approves Gilead's Trodelvy for first-line metastatic triple-negative breast cancer, expanding use alone and with Keytruda. 
Via Benzinga
News headline image
This ETF Has More Than Doubled the S&P 500's Returns Over the Past Decade. Is It a Buy for the Next Decade? ↗
It may not duplicate those impressive results, but it has all the tools it needs. 
Via The Motley Fool
Topics Artificial Intelligence ETFs Stocks
< Previous 1 2 3 4 5 6 7 8 9
...
55 56 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.